BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 12858452)

  • 1. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
    Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
    Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C; Sato S; Takehara K
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
    Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K; Hoch S; Dima C; Varga J; Teodorescu M
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Apr; 24(4):663-5. PubMed ID: 9101498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophils regulate their own apoptosis via preservation of CXC receptors.
    Dunican A; Grutkoski P; Leuenroth S; Ayala A; Simms HH
    J Surg Res; 2000 May; 90(1):32-8. PubMed ID: 10781372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum interleukin 23 in patients with systemic sclerosis.
    Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
    J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated vascular endothelial growth factor in systemic sclerosis.
    Choi JJ; Min DJ; Cho ML; Min SY; Kim SJ; Lee SS; Park KS; Seo YI; Kim WU; Park SH; Cho CS
    J Rheumatol; 2003 Jul; 30(7):1529-33. PubMed ID: 12858453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.